Placebo News and Research

RSS

Significant update to PROGRESS-CTO International Registry presented at SCAI Scientific Sessions 2018

A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total Occlusion Intervention) International Registry was presented today as late-breaking clinical science at Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions 2018.

28 Apr 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

27 Apr 2018

Vitamin B6 could help people to recall their dreams

New research from the University of Adelaide has found that taking vitamin B6 could help people to recall their dreams.

27 Apr 2018

Study to examine whether cannabidiol provides therapeutic benefit to children with autism

Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol, a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder.

27 Apr 2018

Probiotics may be safe, low-cost prevention tool for Clostridium difficile infections

Probiotics may be a relatively safe, simple, and low-cost solution for preventing Clostridium difficile infections in hospital settings, according to two studies published today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

26 Apr 2018

FDA re-examining safety of new drug approved for Parkinson’s disease psychosis

The United States Food and Drug Administration (FDA) is looking again at the safety of a drug Nuplazid that was approved earlier in 2016. This is the only drug that has been approved for the treatment of psychiatric manifestations such as hallucinations and delusions that are associated with Parkinson's disease.

26 Apr 2018

New app could improve safety of cannabis use

Although cannabis, also known as marijuana, has been shown to impair memory, reaction time and attention, it is difficult to assess this impairment in a natural setting. Researchers have developed a prototype app called 'Am I Stoned' that could help cannabis users understand how the drug is affecting them through a series of phone-based tasks.

25 Apr 2018

Clinical trial to examine stem cell therapy for treatment, prevention of complications after traumatic injury

The University of Texas Health Science Center at Houston has received funding through a public/private partnership for the first-ever clinical trial investigating a stem cell therapy for early treatment and prevention of complications after severe traumatic injury.

23 Apr 2018

Nutraceuticals could play an important role in preventing heart disease

Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University of Colorado Boulder research.

20 Apr 2018

FDA approves marijuana based medication for epilepsy treatment

An advisory panel from the United States Food and Drug Administration (FDA) has recommended the approval of a novel epilepsy drug that is made up of ingredients from marijuana. The agency normally follows the recommendations of the advisory panels regarding approvals and rejections of applications of new drugs. The recommendation statement came yesterday (19th April 2018).

19 Apr 2018

NovaDigm Therapeutics initiates NDV-3A Phase 2a study for reduction of S. aureus in military trainees

NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees.

19 Apr 2018

Compound derived from immune cells treats psoriasis in mice

A compound derived from immune cells treats psoriasis in mice and holds promise for other autoimmune diseases, according to a new study from Washington University School of Medicine in St. Louis.

18 Apr 2018

New drug for migraine in the pipeline

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

18 Apr 2018

Study compares survival outcomes of different drugs for type 2 diabetes

In a comparison of different classes of drugs used to lower blood sugar levels for patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1(GLP-1) agonists were associated with a lower risk of death than dipeptidyl peptidase 4 (DPP-4) inhibitors or control (placebo or no treatment).

17 Apr 2018

One class of diabetes drug not associated with reduced risk of death

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.

17 Apr 2018

Antioxidant treatment may decrease cardiovascular risk in women with type 1 diabetes

The high estrogen levels that typically afford younger women protection from cardiovascular disease appear to instead multiply their risk if they have type 1 diabetes, researchers say.

17 Apr 2018

Intranasal formulation of ketamine shows promise in rapid treatment of depression, suicidality

A nasal spray formulation of ketamine shows promise in the rapid treatment of symptoms of major depression and suicidal thoughts, according to a new study published online today in The American Journal of Psychiatry.

16 Apr 2018

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis who have had an incomplete response to ursodeoxycholic acid.

13 Apr 2018

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy to standard sorafenib treatment compared with using sorafenib alone.

13 Apr 2018

Placebo News and Research

Significant update to PROGRESS-CTO International Registry presented at SCAI Scientific Sessions 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

Vitamin B6 could help people to recall their dreams

Study to examine whether cannabidiol provides therapeutic benefit to children with autism

Probiotics may be safe, low-cost prevention tool for Clostridium difficile infections

FDA re-examining safety of new drug approved for Parkinson’s disease psychosis

New app could improve safety of cannabis use

Clinical trial to examine stem cell therapy for treatment, prevention of complications after traumatic injury

Nutraceuticals could play an important role in preventing heart disease

FDA approves marijuana based medication for epilepsy treatment

NovaDigm Therapeutics initiates NDV-3A Phase 2a study for reduction of S. aureus in military trainees

Compound derived from immune cells treats psoriasis in mice

New drug for migraine in the pipeline

Study compares survival outcomes of different drugs for type 2 diabetes

One class of diabetes drug not associated with reduced risk of death

Antioxidant treatment may decrease cardiovascular risk in women with type 1 diabetes

Intranasal formulation of ketamine shows promise in rapid treatment of depression, suicidality

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

Study confirms no survival benefit of adding SIRT to standard treatment for liver cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News